Tough Iain R, Holliday Nicholas D, Cox Helen M
Wolfson Centre for Age-Related Diseases, King's College London, Guy's Campus, London SE1 1UL, UK.
J Pharmacol Exp Ther. 2006 Oct;319(1):20-30. doi: 10.1124/jpet.106.106500. Epub 2006 Jun 28.
The antisecretory effects of several Y agonists, including pancreatic polypeptide (PP), indicate the presence of Y(1), Y(2), and Y(4) receptors in mouse and human (h) colon mucosae. Here, we used preparations from human and from wild-type (WT), Y(4), and Y(1) receptor knockout ((-/-)) mice, alongside Y(4) receptor-transfected cells to define the relative functional contribution of the Y(4) receptor. First, rat (r) PP antisecretory responses were lost in murine Y(4)(-/-) preparations, but hPP and Pro(34) peptide YY (PYY) costimulated Y(4) and Y(1) receptors in WT mucosa. The Y(1) antagonist/Y(4) agonist GR231118 [(Ile,Glu,Pro,Dpr,Tyr,Arg,Leu,Arg,Try-NH(2))-2-cyclic(2,4'),(2',4)-diamide] elicited small Y(4)-mediated antisecretory responses in human tissues pretreated with the Y(1) antagonist, BIBO3304 [(R)-N-[[4-(aminocarbonylaminomethyl)-phenyl]methyl]-N(2)-(diphenylacetyl)-argininamide trifluoroacetate)], and attenuated Y(4)-mediated hPP responses in mouse and human mucosa. GR231118 and rPP were also antisecretory in hY(4)-transfected epithelial monolayers but were partial agonists compared with hPP at this receptor. In Y(4)-transfected human embryonic kidney (HEK) 293 cells, Y(4) ligands displaced [(125)I]hPP binding with orders of affinity (pK(i)) at human (hPP = rPP > GR231118 > Pro(34)PYY = PYY) and mouse (rPP = hPP > GR231118 > Pro(34)PYY > PYY) Y(4) receptors. GR231118- and rPP-stimulated guanosine 5'-3-O-(thio)triphosphate binding through hY(4) receptors with significantly lower efficacy than hPP. GR231118 marginally increased basal but abolished further PP-induced hY(4) internalization to recycling (transferrin-labeled) pathways in HEK293 cells. Taken together, these findings show that Y(4) receptors play a definitive role in attenuating colonic anion transport and may be useful targets for novel antidiarrheal agents due to their limited peripheral expression.
包括胰多肽(PP)在内的几种Y激动剂的抗分泌作用表明,小鼠和人结肠黏膜中存在Y(1)、Y(2)和Y(4)受体。在此,我们使用了来自人以及野生型(WT)、Y(4)和Y(1)受体基因敲除(-/-)小鼠的组织样本,同时使用Y(4)受体转染细胞来确定Y(4)受体的相对功能作用。首先,大鼠(r)PP的抗分泌反应在小鼠Y(4)(-/-)组织样本中消失,但人PP和Pro(34)肽YY(PYY)在WT黏膜中共同刺激Y(4)和Y(1)受体。Y(1)拮抗剂/Y(4)激动剂GR231118 [(Ile,Glu,Pro,Dpr,Tyr,Arg,Leu,Arg,Try-NH(2))-2-环(2,4'),(2',4)-二酰胺]在预先用Y(1)拮抗剂BIBO3304 [(R)-N-[[4-(氨基羰基氨基甲基)-苯基]甲基]-N(2)-(二苯基乙酰基)-精氨酸酰胺三氟乙酸盐]处理的人体组织中引发了小的Y(4)介导的抗分泌反应,并减弱了小鼠和人黏膜中Y(4)介导的人PP反应。GR231118和rPP在人Y(4)转染的上皮单层中也具有抗分泌作用,但与该受体处的人PP相比是部分激动剂。在Y(4)转染的人胚肾(HEK)293细胞中,Y(4)配体以不同亲和力顺序(pK(i))取代[(125)I]人PP结合,在人(人PP = 大鼠PP > GR231118 > Pro(34)PYY = PYY)和小鼠(大鼠PP = 人PP > GR231118 > Pro(34)PYY > PYY)Y(4)受体上。GR231118和大鼠PP通过人Y(4)受体刺激鸟苷5'-3-O-(硫代)三磷酸结合,其效力明显低于人PP。GR231118略微增加基础状态,但在HEK293细胞中消除了进一步的PP诱导的人Y(4)内化至再循环(转铁蛋白标记)途径。综上所述,这些发现表明Y(4)受体在减弱结肠阴离子转运中起决定性作用,并且由于其外周表达有限,可能是新型止泻药的有用靶点。